Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28326222 | 1.00 | SMPD1 (0.48) | SMPD1OPRM1LMNATSHRTHRB | |
| SCHEMBL3506724 | 1.00 | SMPD1 (0.48) | SMPD1OPRM1LMNATSHRTHRB | |
| SCHEMBL113618 | 1.00 | SMPD1 (0.48) | SMPD1OPRM1LMNATSHRTHRB | |
| SCHEMBL3506995 | 1.00 | SMPD1 (0.48) | SMPD1OPRM1LMNATSHRTHRB | |
| SCHEMBL8930848 | 1.00 | SMPD1 (0.48) | SMPD1OPRM1LMNATSHRTHRB | |
| SCHEMBL3506094 | 1.00 | SMPD1 (0.48) | SMPD1OPRM1LMNATSHRTHRB | |
| SCHEMBL6666312 | 1.00 | SMPD1 (0.48) | SMPD1OPRM1LMNATSHRTHRB | |
| SCHEMBL7549190 | 1.00 | SMPD1 (0.48) | SMPD1OPRM1LMNATSHRTHRB | |
| SCHEMBL872866 | 1.00 | SMPD1 (0.48) | SMPD1OPRM1LMNATSHRTHRB | |
| SCHEMBL3380382 | 0.97 | OPRM1 (0.48) | SMPD1OPRM1LMNATSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3556464-B1 | METHOD FOR PRODUCING REDUCED HALIDE COMPOUND HAVING UNDERGONE REDUCTION OF CARBON-CARBON UNSATURATED BOND | SHINETSU CHEMICAL CO (JP) | 2023-08-02 | — | — | EP | disclosed |
| CN-110386863-B | Method for producing reduced halide having reduced carbon-carbon unsaturated bond | 信越化学工业株式会社 | 2023-02-28 | — | — | CN | disclosed |
| US-10676417-B2 | Method for producing reduced halide compound having undergone reduction of carbon-carbon unsaturated bond | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
| CN-110386863-A | The method for being prepared with the reduced form halide that carbon-to-carbon unsaturated bond is reduced | 信越化学工业株式会社 | 2019-10-29 | — | — | CN | disclosed |
| US-20190322607-A1 | METHOD FOR PRODUCING REDUCED HALIDE COMPOUND HAVING UNDERGONE REDUCTION OF CARBON-CARBON UNSATURATED BOND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| EP-3556464-A1 | METHOD FOR PRODUCING REDUCED HALIDE COMPOUND HAVING UNDERGONE REDUCTION OF CARBON-CARBON UNSATURATED BOND | Shin-Etsu Chemical Co., Ltd. (JP) | 2019-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322607-A1 | METHOD FOR PRODUCING REDUCED HALIDE COMPOUND HAVING UNDERGONE REDUCTION OF CARBON-CARBON UNSATURATED BOND | CBR1, CBR3, DECR1 | SMPD1 4295/4885OPRM1 3998/4885LMNA 2999/4885 |
| US-10676417-B2 | Method for producing reduced halide compound having undergone reduction of carbon-carbon unsaturated bond | CBR1, CBR3, DECR1 | SMPD1 4295/4885OPRM1 3998/4885LMNA 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.